iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?

Invesco Biotechnology & Genome ETF (PBE) returned 46.7% over the past year versus 27.4% for iShares U.S. Healthcare ETF (IYH), but PBE carries a higher 0.58% expense ratio and suffered a 34.7% five-year maximum drawdown, compared with IYH's 0.38% fee and 17.9% drawdown. IYH offers broader exposure across 100 healthcare holdings and $3.9B in AUM, while the $404.8M PBE is a concentrated 31-stock biotechnology and genomics allocation. The article favors IYH as a lower-cost, diversified long-term healthcare core holding, with PBE suited to investors accepting greater concentration and volatility for biotech upside.

Analysis

The relevant portfolio question is not broad healthcare versus biotech, but whether recent biotech leadership reflects a durable earnings-revision cycle or a factor-driven rebound from depressed relative valuations. PBE's rules-based concentration can mechanically increase exposure to names after momentum improves, creating procyclical flows and greater reversal risk if FDA decisions, trial readouts, or M&A expectations disappoint. Its smaller asset base also makes it a less efficient institutional vehicle for a large directional allocation; use liquid single names or XBI/IBB for tactical biotech beta instead.

IYH is materially less diversified than its headline position count suggests: LLY, JNJ and ABBV create a large-cap pharma concentration, leaving performance sensitive to GLP-1 durability, drug-pricing policy, and patent-cliff management. The likely second-order winner of sustained biotech strength is AMGN and REGN, where commercial cash flows can fund business development; smaller platform names such as CDNA remain more dependent on financing conditions and idiosyncratic reimbursement/clinical execution. Over 1-3 months, the key catalyst is the cadence of FDA decisions and biotech M&A premiums; over 6-18 months, relative performance will hinge on whether innovation converts into revenue rather than simply higher pipeline valuations.

Consensus may be understating the correlation between the two products during a healthcare risk-off event: both retain substantial exposure to large-cap drug manufacturers, while PBE adds concentrated binary risk rather than true diversification. The recent performance gap is therefore insufficient evidence of a regime change. A better expression is selective: own profitable large-cap biotech into pipeline catalysts and avoid paying for broad, post-rally genomics exposure until earnings revisions validate the move.

Key Decisions for Investors

• No new strategic allocation to PBE after its sharp trailing return; monitor its relative performance versus IYH/XBI for 4-8 weeks. Reassess only if biotech earnings estimates rise alongside relative strength, rather than on FDA/M&A headlines alone.
• For defensive healthcare exposure over 6-12 months, prefer IYH only as a core sleeve and cap it for LLY/ABBV/JNJ concentration risk. Reduce if LLY obesity-franchise guidance, ABBV Skyrizi/Rinvoq growth, or JNJ litigation reserves weaken materially.
• Tactical pair: long AMGN and REGN versus a basket short of high-beta, pre-profit biotech exposure for 1-3 months, sized small around clinical/FDA calendars. The thesis is that cash-generative acquirers capture M&A optionality while speculative targets remain exposed to financing and trial-risk; cover if biotech breadth expands and smaller-cap earnings revisions turn positive.
• Watch CDNA rather than initiate on sector momentum. A position requires independently verified reimbursement adoption, accelerating test volumes, and a financing runway sufficient to avoid dilution; absent those data, the apparent genomics upside is not an actionable risk/reward.